Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma |
| |
| Authors: | O. F. BALLESTER,,L. C. MOSCINSKI,,K. K. FIELDS,,J. W. HIEMENZ,,P. E. ZORSKY,,S. C. GOLDSTEIN,,H. I. SABA,,A. S. D. SPIERS,,L. KRONISH,,P. SULLIVAN, & G. J. ELFENBEIN |
| |
| Affiliation: | Divisions of Bone Marrow Transplantation, Pathology and Hematology/Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, U.S.A. |
| |
| Abstract: | We evaluated toxicities and responses to a novel, dose intensive and time sequenced, chemotherapy programme (DC-IE) in 45 patients with high-risk myeloma. DC-IE consisted of: dexamethasone (days 1–4); cyclophosphamide (day 5); idarubicin and etoposide (days 8–10). Complete response (CR) was achieved in four patients, six patients achieved near complete responses (nCR) and 21 patients achieved a partial remission (PR). Overall response rate was 76% (CI 56–94%) for newly diagnosed patients ( n =21) and 62% (CI 36–81%) for relapsed/refractory patients ( n =24). Toxicities were limited to myelosupression; two patients died of sepsis during neutropenia (4%). DC-IE is active and tolerable for high-risk multiple myeloma, including patients with relapsed or refractory disease to anthracycline containing regimens. |
| |
| Keywords: | myeloma induction chemotherapy time sequenced idarubicin etoposide |
|
|
